Prediction of the effect of 5'-deoxy-5-fluorouridine by the status of angiogenic enzyme thymidine phosphorylase expression in recurrent breast cancer patients

Oncology Reports

Volumn 3, Issue 5, 1996, Pages 863-865

  Yamamoto, Yutaka ^a   Toi, Masakazu ^a   Tominaga, Takeshi ^a  

^a TOKYO METROPOLITAN KOMAGOME HOSPITAL   (Japan)

Author keywords

5'DFUR; breast cancer; PD ECGF; thymidine phosphorylase

Indexed keywords

ANTINEOPLASTIC AGENT; COMPLEMENTARY DNA; CYCLOPHOSPHAMIDE; DOXIFLURIDINE; DOXORUBICIN; FLUOROURACIL; PLATELET DERIVED ENDOTHELIAL CELL GROWTH FACTOR; THYMIDINE PHOSPHORYLASE;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; ENZYME ACTIVITY; FEMALE; GENE EXPRESSION; HUMAN; IMMUNOCYTOCHEMISTRY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RECURRENT CANCER; TREATMENT OUTCOME; TUMOR BLOOD FLOW;

EID: 0029811786     PISSN: 1021335X     EISSN: None     Source Type: Journal    
DOI: 10.3892/or.3.5.863     Document Type: Article

References (14)

1. Hara Y: 5′-deoxy-5-fluorouridine enzymatic activation from the masked compound to 5-fluorouracil in human malignant tissues. Jpn J Cancer Chemother 11: 2133-2143, 1984.
2. Furukawa T, Yoshimura A, Sumizawa T, et al: Angiogenic factor. Nature 356: 668, 1992.
3. Haraguchi M, Miyadera K, Uemura K, et al: Angiogenic activity of enzymes. Nature 368: 198, 1994.
4. Toi M, Hoshina S, Taniguchi T, Yamamoto Y, et al: Expression of platelet-derived endothelial cell growth factor/thymidine phosphorylase in human breast cancer. Int J Cancer 64: 79-82, 1995.
5. Cook AF, Homan MJ, Karmar MJ, et al: Fluorinated pyrimidine nucleosides. Synthesis and antitumor activity of a series of 5′-deoxy-5-fluoropyrimidine nucleosides. J Med Chem 22: 1330-1335, 1979.
6. Ishitsuka H, Miwa M, Takemoto K, et al: Role of uridine phosphorylase for antitumor activity of 5′-deoxy-5-fluorouridine. Jpn J Cancer Chemother 71: 112-123, 1980.
7. Nitani H, Kimura K, Saito T, et al: Phase II study of 5′-deoxy-5-fluorouridine on patients with malignant cancer - multiinstitutional cooperative study. Jpn J Cancer Chemother 12: 2044-2051, 1985.
8. Haraguchi M, Furukawa T, Sumizawa T, et al: Sensitivity of human KB cells expressing platelet-derived endothelial cell growth factor to pyrimidine antimetabolites. Cancer Res 53: 5680-5682, 1993.
9. Tominaga T, Abe O, Ohshima A, et al: Comparison of chemotheraphy with or without medoroxyprogesteron acetate for advanced or recurrent breast cancer. Eur J Cancer 30: 959-964, 1994.
10. Toi M, Inada K, Hoshina S, et al: Vascular endothelial growth factor and platelet-derived endothelial cell growth factor are frequently coexpressed in highly vascularized human breast cancer. Clin Cancer Res 1: 961-964, 1995.
11. Takebayashi Y, Yamada K, Maruyama I, et al: The expression of thymidine phosphorylase and thrombomodulin in human colorectal carcinomas. Cancer Lett 92: 1-7, 1995.
12. Moghaddam A, Zhang H, Fan TD, et al: Thymidine phosphorylase is angiogenic and promotes tumor growth. Proc Natl Acad Sci USA 92: 998-1002, 1995.
13. Eda H, Fujimoto K, Watanabe S, et al: Cytokines induce thymidine phosphorylase expression in tumor cells and make them more susceptible to 5′-deoxy-5-fluorouridine. Cancer Chemother Pharmacol 32: 333-338, 1993.
14. Ishikawa T, Ura M, Yamamoto T, et al: Selective inhibition of spontaneous pulmonary metastases of Lewis lung carcinoma by 5′-deoxy-5-fluorouridine. Int J Cancer 61: 516-521, 1995.